Home » Stocks » Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. (ZNTL)

Stock Price: $29.40 USD -2.10 (-6.67%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.18B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 40.00M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $29.40
Previous Close $31.50
Change ($) -2.10
Change (%) -6.67%
Day's Open 32.11
Day's Range 29.40 - 32.87
Day's Volume 370,254
52-Week Range 22.00 - 59.32

More Stats

Market Cap 1.18B
Enterprise Value 942.48M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 40.00M
Float 30.79M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.43M
Short Ratio 19.18
Short % of Float 15.25%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.91
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 233.60M
Net Cash / Share 5.84
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(53.06% upside)
Current: $29.40
Target: 45.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-0.01
Operating Income-46.85-23.78
Net Income-45.66-21.07
Shares Outstanding5.605.59
Earnings Per Share-8.16-3.77
Operating Cash Flow-39.14-24.25
Capital Expenditures-0.35-0.23
Free Cash Flow-39.50-24.48
Cash & Equivalents67.4925.15
Net Cash / Debt67.4925.15
Book Value-80.1124.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zentalis Pharmaceuticals, Inc.
Country United States
Employees 75
CEO Anthony Y. Sun

Stock Information

Ticker Symbol ZNTL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZNTL
IPO Date April 3, 2020


Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York. Address: 530 Seventh Avenue, New York, NY, United States, 10018